- Home
- GHI vs NTHI Comparison
GHI vs NTHI Comparison
Compare GHI & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | NTHI |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3M | 114.6M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | GHI | NTHI |
|---|---|---|
| Price | $5.21 | $3.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.50 | ★ $15.00 |
| AVG Volume (30 Days) | 66.2K | ★ 88.7K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | ★ 22.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $85,389,766.00 | N/A |
| Revenue This Year | $273.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $527.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.71 | $3.01 |
| 52 Week High | $11.45 | $12.99 |
Technical Indicators
Market Signals| Indicator | GHI | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 26.75 |
| Support Level | $5.05 | N/A |
| Resistance Level | $5.52 | $5.78 |
| Average True Range (ATR) | 0.18 | 0.35 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 8.25 | 19.75 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.